Comparative study of reference points by dosimetric analyses for late complications after uniform external radiotherapy and high-dose-rate brachytherapy for cervical cancer

• Published in: International journal of radiation oncology, biology, physics Vol. 60; no. 2; pp. 663 - 671
• Main Authors: Chen, Shang-Wen, Liang, Ji-An, Yeh, Lian-Shung, Yang, Shih-Neng, Shiau, An-Cheng, Lin, Fang-Jen
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.10.2004
• Subjects: Brachytherapy; Cervical cancer; Late sequelae; Radiation dose; Radiation dose; Brachytherapy; Late sequelae; Cervical cancer
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2004.05.028

This study aimed to correlate and compare the predictive values of rectal and bladder reference doses of uniform external beam radiotherapy without shielding and high-dose-rate intracavitary brachytherapy (HDRICB) with late sequelae in patients with uterine cervical cancer. Between September 1992 and December 1998, 154 patients who survived more than 12 months after treatment were studied. Initially, they were treated with 10-MV X-rays (44 to 45 Gy/22 to 25 fractions over 4 to 5 weeks) to the whole pelvis, after which HDRICB was performed using 192Ir remote afterloading at 1-week intervals for 4 weeks. The standard prescribed dose for each HDRICB was 6.0 Gy to point A. Patient- and treatment-related-factors were evaluated for late rectal complications using logistic regression modeling. The probability of rectal complications showed better correlation of dose–response with increasing total ICRU (International Committee on Radiotherapy Units and Measurements) rectal dose. Multivariate logistic regression demonstrated a high risk of late rectal sequelae in patients who developed rectal complications ( p = 0.0001;relative risk, 15.06;95% CI, 2.89∼43.7) and total ICRU rectal dose greater than 16 Gy ( p = 0.02;relative risk, 2.07;95% CI, 1.13∼4.55). The high risk factors for bladder complications were seen in patients who developed rectal complications ( p = 0.0001;relative risk, 15.2;95% CI, 2.81∼44.9) and total ICRU bladder dose greater than 24 Gy ( p = 0.02;relative risk, 8.93;95% CI, 1.79∼33.1). This study demonstrated the predictive value of ICRU rectal and bladder reference dosing in HDRICB for patients receiving uniform external beam radiation therapy without central shielding. Patients who had a total ICRU rectal dose greater than 16 Gy, or a total ICRU bladder dose over 24 Gy, were at risk of late sequelae.